Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study

BMC Research Notes

Jesús Rodríguez-Baño¹  Miguel Angel Muniain¹  Virginia Palomo²  Felipe Fernández-Cuenca²  Angel Domínguez-Castellano¹  Juan Gálvez-Acebal¹  María José Ríos-Villegas¹  Carmen Machado² 

[1] Departament of Medicine, University of Seville, Seville, Spain;Infectious Diseases Unit, Hospital Universitario Virgen Macarena. Seville, Avda Dr Fedriani 3, Seville, 41009, Spain

关键词: Cohort study;    Outcome;    Treatment interruption;    Antiretroviral therapy;    HIV-1;   

Others  :  1165429
DOI  :  10.1186/1756-0500-5-578

 received in 2012-08-28, accepted in 2012-10-17,  发布年份 2012

【 摘 要 】

Background

To describe the long term outcome of patients who interrupted highly active antiretroviral therapy (HAART) once, identify the variables associated with earlier need to re-start HAART, and the response when therapy was resumed. A retrospective observational cohort of 66 adult patients with HIV-1 infection who interrupted HAART with a CD4+cell count ≥350 cells/μL and undetectable viral load (VL) was performed. The pre-established CD4+ cell count for restarting therapy was 300cells/μL. Cox regression was used to analyse the variables associated with earlier HAART reinitiation.

Results

The median follow-up was 209 weeks (range, 64–395). Rates of HIV-related or possible HIV-related events were 0.37 (one case of acute retroviral syndrome) and 1.49 per 100 patient-years, respectively. Two patients died after re-starting therapy and having reached undetectable VL. Three patients suffered a sexually transmitted disease while off therapy. Fifty patients (76%) resumed therapy after a median of 97 weeks (range, 17–267). Age, a nadir of CD4+ <250 cells/μL, and a mean VL during interruption of >10,000 copies/ml were independent predictors for earlier re-start. The intention-to-treat success rate of the first HAART resumed regimen was 85.4%. There were no differences by regimen used, nor between regimens that were the same as or different from the one that had been interrupted.

Conclusions

Our data suggest highly active antiretroviral therapy may be interrupted in selected patients because in these patients, when the HAART is restarted, the viral and clinical response may be achieved.

【 授权许可】

   
2012 Machado et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Mocroft A, Lundgren JD: Starting highly active antiretroviral therapy: why, when and response to HAART. J Antimicrob Chemother 2004, 54:10-13.
• [2]Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2011, 1-167. Disponible en: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf webcite. Consultado el 11/12/2011
• [3]European AIDS Clinical Society (EACS). Guidelines, version 6.1 2011. Disponible en: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf webcite. Consultado el 11/12/2011
• [4]Panel de expertos de GESIDA y Plan Nacional sobre el Sida: Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el VIH (Actualización 01.2011). Enferm Infecc Microbiol Clin 2011, 29:e1-e103. Disponible en: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011-Documentoconsenso-TAR-adulto-verimprimir.pdf webcite. Consultado el 11/12/2011
• [5]Pai NP, Tulsky JP, Lawrence J, Colford JM, Reingold AL: Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005, 4:CD005482.
• [6]Seminari E, De Silvestri A, Boschi A, Tinelli C: CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS rev 2008, 10:236-244.
• [7]Knobel H, Urbina O, González A, Sorlí ML, Montero M, Carmona A, et al.: Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up. HIV Med 2009, 10:364-369.
• [8]Center for Diseases Control and Prevention (CDC): 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992, 41(RR-17):1-19.
• [9]Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, Centers for Disease Control and Prevention (CDC): Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep 2008, 57(RR-10):1-12.
• [10]Eron JJ: Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. Journal Infectious Diseases 2008, 197(Suppl. 3):261-271.
• [11]Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al.: Validation of a simplified adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002, 16:605-613.
• [12]Maggiolo F, Airoldi M, Callegaro A, et al.: CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009, 23:799-807.
• [13]Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, et al.: Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007, 195:1426-1436.
• [14]Amador C, Pasquau F, Ena J, de Apodaca RF BCyR: Interrupción del tratamiento antirretroviral en pacientes con infección crónica por el virus de la inmunodeficiencia humana. Med Clin 2005, 125:41-45.
• [15]Mata RC, Viciana P, De Alarcon A, et al.: Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunological consequences. AIDS Patient Care and STDs 2005, 19:6-18.
• [16]Cervero-Jiménez M, Torres-Perea R, Ruiz-Capillas JJ, Álamo M, Agud JL, Solís J, et al.: Factores que predicen el fracaso de las interrupciones del tratamiento antirretroviral (TAR) en los pacientes con infección por el VIH. Enferm Infecc Microbiol Clin 2005, 23:202-207.
• [17]Teicher E, Casagrande T, Vittecoq D: Enchanced risk of HIV sexual transmission during structured treatment interruption. Sex Trans Infect 2003, 79:74.
• [18]Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, et al.: Antiretroviral therapy interruptions guided by CD4 cell count and plasma HIV_1 RNA levels in chronically HIV-1 infected patients. AIDS 2007, 21:169-178.
• [19]Arnedo-Valero M, García F, Gil C, Guila T, Fumero E, Castro P, et al.: Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in pacients with chronic HIV infection. Clin Infect Dis 2005, 41:883-890.